UMGCCC Clinical Trials

  • More About Clinical Trials
  • Deciding to Enroll
  • Questions to Ask
  • For More Information
  • Research
  • Cancer Overviews
  • Treatment Programs
  • Physicians and Staff
Protocol SummaryBack To Search Instructions
Protocol No.AHOD1331Principal InvestigatorYork, Teresa
PhasePhase III
Age GroupBoth
TitleA Randomized Phase III Study of Brentuximab Vedotin (Bv, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Applicable Disease SitesHodgkin Lymphoma
StatusOpen
Treatment TypeTreatment
ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02166463
ContactGreenebaum Comprehensive Cancer Center: Natalie McNally, MS, CCRP Phone:410-328-2808
Pager:410-328-2337 #7041
Email:nmcnally@peds.umaryland.edu
Back to Protocol Listing